9 October 2022 - Innovent Biologics is pleased to see that the NMPA of China has approved the new drug application ...
28 September 2022 - Toray Industries announced today that it has received approval from China’s NMPA for Careload tablets to treat ...
22 September 2022 - One in two women with advanced ovarian cancer has an HRD positive tumour. ...
20 September 2022 - Sixth approved indication of toripalimab in China, bringing more treatment options to patients with advanced non-small-cell ...
13 September 2022 - GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with ...
7 September 2022 - This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART. ...
6 September 2022 - InnoCare Pharma announced today that BTK inhibitor orelabrutinib has been granted priority review for the treatment of ...
5 September 2022 - Approval marks the first SGLT-2 inhibitor approved in China for chronic kidney disease in adult patients ...
22 August 2022 - Highly accurate, tissue based, next generation sequencing test approved in China as a companion diagnostic for ...
25 July 2022 - Anti-PD-1 monoclonal antibody – Puyouheng (HX-008, pucotenlimab), was conditionally approved by the NMPA for marketing in China ...
22 July 2022 - In China, efforts to qualify innovative medical products for reimbursement used to be subject to substantial delays ...
19 July 2022 - Ascentage Pharma and Innovent Biologics today announce that the Center for Drug Evaluation of China's NMPA ...
15 July 2022 - Neurophth Therapeutics today announced that the Center for Drug Evaluation of China National Medical Products Administration has ...
13 July 2022 - Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for generalised myasthenia gravis ...
8 July 2022 - High prices of anticancer medicines have increased the economic burden for both patients and health insurance systems. ...